|

TNG456 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Tango Therapeutics, Inc.1

Indications

  • Non-Small Cell Adenocarcinoma1
  • Glioma Glioblastoma Multiforme1
  • Solid Tumor1
  • Glioma, Malignant1
  • Brain Tumor1

Scottsdale, Arizona1 trial

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Mayo Clinic Scottsdale

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.